Correction: Effects of KRAS, STK11, KEAP1, and TP53 mutations on the clinical outcomes of immune checkpoint inhibitors among patients with lung adenocarcinoma.

Where this comes from

• Record sourced from PubMed, PMID 40788850.
• Also identified by DOI 10.1371/journal.pone.0330099 and PMC identifier 12338798.
• No licence information is recorded for this record.
• Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.